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In the rapidly evolving field of primary immunodeficiencies (PID), the EuroFlow
consortium decided to develop a PID orientation and screening tube that facilitates
fast, standardized, and validated immunophenotypic diagnosis of lymphoid PID, and
allows full exchange of data between centers. Our aim was to develop a tool that would
be universal for all lymphoid PIDs and offer high sensitivity to identify a lymphoid PID
(without a need for specificity to diagnose particular PID) and to guide and prioritize
further diagnostic modalities and clinical management. The tube composition has been
defined in a stepwise manner through several cycles of design-testing-evaluation-
redesign in a multicenter setting. Equally important appeared to be the standardized pre-
analytical procedures (sample preparation and instrument setup), analytical procedures
(immunostaining and data acquisition), the software analysis (a multidimensional view
based on a reference database in Infinicyt software), and data interpretation. This
standardized EuroFlow concept has been tested on 250 healthy controls and 99 PID
patients with defined genetic defects. In addition, an application of new EuroFlow
software tools with multidimensional pattern recognition was designed with inclusion of
maturation pathways in multidimensional patterns (APS plots). The major advantage of
the EuroFlow approach is that data can be fully exchanged between different laboratories
in any country of the world, which is especially of interest for the PID field, with generally
low numbers of cases per center.
Keywords: flow cytometric immunophenotyping, primary immunodeficiencies, automated gating strategy,
standardization, EuroFlow
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INTRODUCTION
Primary immunodeficiencies (PID) of the lymphoid
system are rare inherited disorders with heterogeneous clinical
presentations (1, 2). Most patients have clinical manifestations
of immune dysfunction such as recurrent infections (early
in life), and autoimmunity frequently causing irreversible
organ damage in case of delayed diagnosis. As a consequence
fast and efficient diagnostic screening is required. Advanced
multicolor flow cytometry serves on this need. Flow cytometric
immunophenotyping of T, B, and NK cells is the classically
recommended method in the diagnostic work-up in case of a
suspicion of PID of the lymphoid system. The complete diagnosis
and classification consists of stepwise screening and subsequent
characterization for numerical alterations in lymphocyte (sub)
populations, detection of functional defects, and functional
assays. However, lack of standardization and the rarity of PID
has so far complicated a common strategy in PID diagnostics.
The introduction and the availability of next generation
sequencing (NGS) based on targeted panel sequencing or whole
exome sequencing (WES) with a filter for PID genes has an
important impact on PID diagnostics in identification of the
variants in known PID genes (3, 4). Moreover, it contributes
to the broadening of the clinical spectrum of known PIDs.
Finally, WES and whole genome sequencing (WGS) allows
the identification of genetic defects in new PID candidate
genes. However, the turnaround time is relatively long (i.e., a
couple of months in a routine diagnostic setting) in contrast
to flow cytometry, which already provides complete insight
into the composition of the lymphoid compartment within a
day. For correct interpretation of NGS data, it is crucial that
the immunophenotype is known. Furthermore, flow cytometry
can play an important role in the functional validation of
genetic variants to evaluate the impact on the immune system.
Altogether, this illustrates that both NGS and flow cytometry are
valuable tools in PID diagnostics.
In this study, we developed a PID screening and orientation
tube which allows fast and robust detection and enumeration
of the lymphocyte subsets. It is important to notice that more
than 70% of all PID concern inborn defects in the lymphoid
system. Orientation in an early phase of the diagnostic process
forms the basis for consecutive diagnostics, treatment, and
clinical management. Therefore, we need a PID screening and
orientation tube (PIDOT) which allows dissection of especially
the lymphoid compartment in peripheral blood with full
standardization to allow international comparability of results.
METHODS
Patient and Control Samples
Peripheral blood samples were collected from 250 healthy
controls divided into 14 age groups: cord blood (n= 15), neonatal
blood (n= 16), 1–5 month (n= 12), 5–11m (n= 7), 12–24m (n
= 30), 2–4 years (n = 35), 5–9y (n = 28), 10–17y (n = 18), 18–
29y (n= 31), 30–39y (n= 15), 40–49y (n= 12), 50–59y (n= 10),
60–69y (n= 10),>70y (n= 11). Healthy controls were selected as
having no signs or suspicion of immunological or hematological
diseases (including an abnormal infection rate or a known history
of allergies). All individuals were vaccinated following similar
national vaccination schedules (European Center for Disease
Prevention and Control; http://vaccine-schedule.ecdc.europa.eu/
Pages/Scheduler.aspx). They were enrolled at the different
EuroFlow laboratories after informed consent was provided by
each subject, their legal representatives, or both, according to the
Declaration of Helsinki. In addition 99 patients with a genetically
defined PID were collected according to the local medical
ethics regulations of the participating centers. All samples were
collected after informed consent was provided by the subjects,
their legal representatives, or both, according to the Declaration
of Helsinki. The study was approved by the local ethics
committees of the participating centers [University of Salamanca,
Salamanca, Spain (USAL-CSIC 20-02-2013); Charles University,
Prague, Czech Republic (15-28541A); Erasmus MC, Rotterdam,
The Netherlands (MEC-2013-026); University Hospital Ghent,
Belgium (B670201523515) and St Anne‘s University, Brno, Czech
Republic(METC 1G2015)].
Assessment of Absolute Numbers of B, T,
and NK Cells
The absolute number of lymphocytes (B, T, and NK cells)
was determined either in a separate TrueCount (BD)
tube with anti-CD45 PerCP alone or BD MultitestTM
CD3/CD16+CD56/CD45/CD19 or it was determined by
hematological analyser as a part of a diagnostic workup.
Design of the PID Screening Tube
The PID screening tube was designed to assess the composition
of the lymphoid compartment in a single 8-color labeling for
guiding diagnosis of PID patients via detecting all relevant
subpopulations. To this end, at certain fluorochrome positions
two markers, i.e., a B-cell and a T-cell marker were combined of
which is absolutely secured that they are exclusively expressed
on only one of the subsets. So, two similarly labeled antibodies
defining two distinct populations aremixed. CD19 was combined
with TCRγδ, CD4 with IgM, and CD8 with IgD. CD16 and CD56
were already combined on the same channel for detection of NK
cells. In addition to the above mentioned markers, we included
CD3, CD45, CD27, and CD45RA. The optimal combination
of clones and fluorochromes was reached after four rounds
of testing in the participating centers (Supplementary Table 1).
In order to achieve higher sensitivity to low abundant cell
types, we used a lyse-stain-wash-fix protocol and the antibody
staining timewas increased to 30min (6). This optimized staining
procedure yielded more acquired cells (lymphocyte event counts
were in average 2.89 × 10e5 in healthy controls and 1.32 × 10e5
in PID patients) per sample with less non-leukocyte particles
(less debris), and yielded higher median fluorescence intensity
(MFI) patterns for several antibodies (Figure S1). The data were
acquired on BD LSRII or BD FACSCanto II instruments with
the standard EuroFlow instrument settings (7). For data analysis,
the Infinicyt software (Cytognos SL, Salamanca, Spain) was used
in parallel to local data analysis software programs FACS Diva
(BD) and FlowJo (FlowJo, LLC, Ashland, OR, USA). Infinicyt
software is a commercially available product from Cytognos SL
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(Salamanca Spain) and a free-dowload demo version is available
at www.infinicyt.com.
Analysis of Lymphocyte Subsets in Healthy
Controls
The lymphoid PID screening tube was used for analysis of
250 healthy controls of different ages to define the patterns
and to set the reference for the database. All samples were
analyzed in conventional analysis software programs (FlowJo
and FACSDiva) and using Infinicyt Software. In both software
packages the same analysis strategy was followed for definition
of the lymphocyte subsets. Percentile ranges were calculated for
each age group, for unified overview in Figure S2 values in
patients compared to two or five standard deviations of controls
were used.
Analysis of Genetically Defined PID
Patients
Next we tested the lymphoid PID screening tube on 99 genetically
defined PID patients. The patients were classified according to
the IUIS classification, which divides PID into 8 categories. First,
the absolute number and relative frequencies of the lymphocyte
subset populations were determined in all patients. This data set
formed the basis for development of our new approach for flow
cytometry in PID.
Statistical Analyses
Mean and range values were calculated for all continuous
variables using the SPSS statistical software (SPSS software v23,
IBM, Armonk, NY). Data files from 50 healthy donors were
merged and lymphocytes subsets of interest identified using
bivariate plots (Figure). This analysis was used to define in
an n-dimensional space the best principal component analysis
1 (PC1) vs. PC2 representation to discriminate these subsets
using the Infinicyt software. The PCA representation of the
data is graphically summarized in 2 × Standard Deviation
(SD) curves to be used as a reference for supervised automatic
analysis of the samples (APS view; Figures 3–5). In order
to graphically display an overview of abnormalities found
in a PID group adjusted to age, we calculated a relative
distance from age matched healthy controls for each value
in each PID case as a number of standard deviations (SD)
from healthy controls. Values below−2 SD or above 2 SD
are considered abnormal. Repeatedly abnormal values (in
a given PID disease group) are plotted in supplementary
figures. Calculations and graphic displays of the discriminating
parameters (Supplementary Figure 2) were created using R-
project/ Bioconductor http://www.r-project.org and Microsoft
Excel for Mac 2011 (Redmont, WA, USA).
RESULTS
Multidimensional Analysis of the EuroFlow
PID Orientation Tube
In this study, we aimed to advance flow cytometric
immunophenotyping of PID patients by linking the flow
cytometric data to potential immunological defects and by
incorporating this approach into the diagnostic process. To
this end, we designed a PID orientation tube (PIDOT) (8
colors; 14 parameters) that allowed the analysis of all main
lymphocyte subpopulations in a single standardized and
validated tube (Table 1, Figure 1). After gating leukocytes as
CD45+ and lymphocytes on FSc and SSc, the markers CD3,
TABLE 1 | Composition of the EuroFlow PID Screening tube and information of monoclonal antibodies used in the PID screening tube including volumes, clones, and
suppliers.
BV421 BV510 FITC PE PerCP-Cy5,5 PC7/PE-Cy7 APC APC-H7
CD27 CD45RA CD8 CD16 CD4 CD19 CD3 CD45
IgD CD56 IgM TCRgd
Marker Fluorochrome Clone Source Catalog number µl/test
CD3 APC SK7 BD Biosciences 345767 2.5
CD4 PerCPC5.5 SK3 BD Biosciences 332772 7
CD8 FITC SKI BD Biosciences 345772 5
CD16 PE 3G8 BD Biosciences 555407 5
CD19 PECy7 J3-119 Beckman Coulter IM3628 5
CD27 BV421 M-T271 BD Biosciences 562513 1
CD27 alternative BV421 O323 BioLegend 302823 1
CD45 APCH7 2D1 BD Biosciences 641417 2
CD45RA BV510 HI100 BD Biosciences 563031 2.5
CD45RA alternative BV510 HI100 Biolegend 304141 2.5
CD56 PE C5.9 Cytognos CYT-56PE 5
SmIgD FITC IA6-2 BioLegend 348205 1.25
SmIgM PerCPCy5.5 MHM-88 BioLegend 314511 2
TCRγδ PECy7 11F2 BD Biosciences 649806 1
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FIGURE 1 | Flow cytometric analysis of B- and T-cell populations using the EuroFlow PID screening tube, 50 healthy controls are shown in the same plot, median of
each gated subset is shown as a circle. (A) After gating leukocytes as CD45+ and lymphocytes on FSc and SSc, the markers CD3, CD19 in combination with TCRγδ
and CD16+56 were used to define B-cells (orange); TCRγδ+ T-cells (lilac); TCRγδ- T-cells (blue); and NK cells (brown). (B) The T-cell subsets were further subdivided
into naïve (CD27+CD45RA+; dark green), central memory/transitional memory (CM/TM; CD27+CD45RA-; bright green), effector memory (EM; CD27-CD45RA-;
green) and terminally differentiated (TD; CD27-CD45RA+; light green) CD4+ T cells and into naïve (CD27+CD45RA+; purple), CM/TM (CD27+CD45RA-; dark blue),
EM (CD27-CD45-; pale blue), and TD (CD27-CD45RA+; turqoise) CD8+ T cells. Also, as previously reported (5), some effector CD8+ T-cells showed dim CD27
positivity (EffCD27dim; CD27int-CD45RA+; blue). CD4/CD8 double negative T-cells are indicated in light blue. (C) B-cell subsets could be further subdivided into pre
germinal center (PreGC; IgM+ IgD+CD27−; orange) unswitched memory B-cells/plasma cells (Unswitched MBC/PC; IgM+ IgD+/−CD27+; yellow), switched memory
MBC/PC (IgM− IgD−CD27+; pink). (D) Definition and hierarchy of the defined subsets. (E) Multidimensional view (APS view) based on the most discriminating
parameters for lymphocytes, B-cell, T-cells, and T-cell subsets.
CD19 in combination with TCRγδ and CD16+56 were used
to define B-cells, TCRγδ+ or TCRγδ- T-cells and NK cells
(Figure 1A). The T-cell subsets were further subdivided into
naïve, central memory (CM)/transitional memory (TM), effector
memory and terminally differentiated (TD) CD4+/CD8+ T cells
(Figures 1B,D); for CD8+ T-cells one extra population, effector
CD27dim was defined. Also CD4-CD8- (double negative) T-cells
were defined (5). B-cell subsets were further subdivided into pre
germinal center B-cells (PreGC), unswitched memory B-cells
(MBC) or plasma cells (PC), and switched MBC Figures 1C,D)
(8, 9). The total set and hierarchy of lymphocyte subsets that was
identified is listed in Figure 1D.
To offer intuitive and fast interpretation of the complete
lymphoid compartment we developed a new analysis and
visualization strategy for the PIDOT using a principle component
analysis based multidimensional view (APS graph). First,
reference plots were generated using a set of 30 samples of healthy
donors in Infinicyt software. The lymphocyte populations were
manually analyzed and subsequently, the most discriminating
projection into a single APS graph was determined (Figure 1E).
Reference Values and Database
Subsequently, this analysis strategy and visualization was tested
on 250 healthy controls in 14 different age ranges, which resulted
in a unique reference data set of all lymphocyte subsets. All
values of this reference data set are displayed as bar graphs
representing the median, minimum, maximum, and p10, p25,
p75, and p90 percentiles in Figure 2. Finally, 99 genetically
defined PID patients were analyzed to study the performance of
the EuroFlow PIDOT (Table 2).
PID With Absence or Strong Reduction in
One or More Lymphocyte Subsets
The two main categories of PID with absence or strong
reduction in one or more lymphocyte subsets are SCID and
agammaglobulinemia with absent T (NK) and/or B-cells.
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FIGURE 2 | Flow cytometric analysis of B- and T-cell populations using the EuroFlow PIDOT in 250 healthy controls in 14 different age ranges. All values of this
reference data set are displayed as bar graphs representing the median, minimum, maximum, and p10, p25, p75, and p90 percentiles. For data visualization package
gplot2 for the statistical language R was used (10).
SCID
Absence or strong reduction of lymphocyte subsets (B, NK,
CD4, and CD8 T-cells) can be easily established by comparison
of absolute numbers of lymphocyte subsets of patient vs. age-
matched reference values. We analyzed patients with RAG1
(n = 8), RAG2 (n = 5), Artemis (n = 3), IL2RG (n = 6),
IL7RA (n = 1), and ZAP70 (n = 3) deficiencies. In all patients
the CD3-positive T-cells were strongly reduced, except for one
patient with a RAG2 deficiency who presented with a high
number of T-cells. In ZAP70 deficient patients, CD8-positive T-
cells were reduced and in one of them also the CD4-positive
T-cells, although to a lesser extent. NK cells, however, show
a more heterogenous/variable pattern. This illustrates that NK
cell numbers cannot straightforwardly be used for classification
and it supports the idea to leave out NK cells for classification
(11, 12). In addition to evaluation of the absolute counts, the
APS views provide insight into the distribution of the lymphocyte
subsets. RAG deficiencies can give a broad spectrum of clinical
and immunological phenotypes. This partly depends on the type
of mutation and the residual V(D)J recombinase activity (13–15).
On top of that, the same mutation can also be associated with
clinical heterogeneity (14). This phenomenon is also reflected
in the APS profiles of RAG deficiencies (Figure 3A). RAG1,
RAG2 as well as Artemis deficiencies with a null mutation will
result in complete absence of B and T cells (RAG-1 patient
A in Figure 3A). However, in case of a leaky or hypomorphic
mutation T–cells are present (RAG-1 patient B in Figure 3A),
which are in this case all TCRγδ- and had a memory or effector
T-cell phenotype. In such situation the origin of T-cells need to
be determined to investigate whether these T-cells are autologous
or from maternal origin. A third pattern that can be seen is
the presence of both T and B cells (RAG patient C and D). In
both cases both TCRγδ- and TCRγδ+ T-cells are present (with
a memory or effector phenotype) and the B-cells were mainly
naïve or natural effector. No switched memory B cells or plasma
cells were detected. So, the hallmark for RAG deficiencies with
residual T-cells, which is characteristic for Omenn Syndrome, is
absence or strong reduction of naïve CD4 and CD8 T-cells.
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TABLE 2 | Frequency of patients with inborn errors of immunity showing defects
of the major subsets identified in the EF PIDOT, as compared to age-reference
values (Summary of Supplementary Tables 2, 3).
Any T cell
subset
Any B cells
subset
NK
cells
Any of
them
SCID (n = 24) 100% 100% 25% 100%
IL2Rg 6/6 6/6 5/6 6/6
IL7R 1/1 1/1 0/1 1/1
RAG1 8/8 8/8 1/8 8/8
RAG2 5/5 5/5 0/5 5/5
DCLRE1C 3/3 3/3 0/3 3/3
NHEJI 1/1 1/1 0/1 1/1
CID (n = 12) 58% 83% 25% 100%
CD40L 1/6 6/6 0/6 6/6
ZAP70 3/3 1/3 0/3 3/3
DOCK8 2/2 2/2 2/2 2/2
BCL10 1/1 1/1 1/1 1/1
CID with syndromic
features (n = 20)
70% 60% 10% 75%
WASp 3/3 3/3 0/3 3/3
ATM 5/6 4/6 0/6 5/6
Di George 3/6 1/6 0/6 3/6
STAT3 1/2 2/2 1/2 2/2
NEMO 1/2 1/2 0/2 1/2
PNP 1/1 1/1 1/1 1/1
PAD (n = 16) 31% 100% 25% 100%
BTK 1/10 10/10 1/10 10/10
PIK3CD 4/5 5/5 3/5 5/5
AID 0/1 1/1 0/1 1/1
Disease of immune
dysregulation (n = 10)
70% 60% 10% 90%
Syntaxin 1/1 1/1 0/1 1/1
FAS 5/5 2/5 1/5 5/5
XLP 0/1 1/1 0/1 1/1
CD27 1/1 1/1 0/1 1/1
CTPS1 0/2 1/2 0/2 1/2
Defects of phagocytes
or function (n = 10)
30% 60% 40% 70%
CGD 1/5 3/5 1/5 3/5
GATA2 2/5 3/5 3/5 4/5
Defects innate
immunity (n = 3)
67% 67% 33% 67%
STAT1 1/1 1/1 1/1 1/1
WHIM 1/1 1/1 0/1 1/1
IRAK4 0/1 0/1 0/1 0/1
Complement
deficiencies (n = 4)
0% 0% 0% 0%
Results expressed as percentage of patients showing absolute counts below the lower
limit of normality, compared to age-reference values obtained from 250 healthy donors
analyzed with the same protocol. SCID, Severe Combined Immunodeficiency; CID,
Combined Immunodeficiency; PAD, Predominantly Antibody Deficiency.
In IL2RG, IL7RA and ZAP70 deficiencies B-cell numbers were
normal. IL2RG and IL7RA deficiency have in common that all B-
cells have a naïve phenotype, which is in line with the fact that T-
cell help is lacking for further differentiation (Figure 3B). In the
ZAP70 deficiency some natural effector and switched memory
B-cells are present. In case T-cells were present in patients with
IL2RG deficiency, they had a memory phenotype (IL2RG B and
C, Figure 3B).
Agammaglobulinemia
A second clear cut example in which lymphocyte subset analysis
is highly informative in PID diagnostics is absence of B-cells in
the 10 patients with X-linked agammaglobulinemia. The absolute
number of B-cells is strongly reduced or the B-cells are even
absent. As shown by the APS plots, if B-cells are present, they
only have a naive phenotype (Figure 4A). The advantage of this
approach is that on top of the maturation pathway that can be
visualized with the APS plots, novel information can be obtained.
The expression level within the naïve B-cells is shifted, indicating
that the phenotype of this population also differs from normal.
Disturbed Distribution Patterns of
Lymphocyte Subsets in PID
In certain PID a specific distribution of lymphocyte subsets
can be observed, which serves as a hallmark of the disease. A
genetic defect in CD40L results in disturbed B-T interaction and
consequently in reduced generation of (switched) memory B-
cells that are T-cell dependent (16). As shown in a representative
case, patients with CD40L deficiency have normal numbers of
total B-cells, but they mainly consist of naïve or unswitched
memory B-cells (Figure 4A). A second example is autoimmune
lymphoproliferative disease (ALPS) mainly caused by mutations
in FAS and FASL, which is characterized by the presence of
a high frequency of TCRαβ+CD4-CD8- T-cells (i.e., double
negative T-cells) (Figure 4A, Figure S2). Disturbed distributions
of lymphocyte subsets or combinations of lymphocyte subsets
can also be observed in other PID cases such as patients
with WAS, ATM, DOCK8 deficiency, or DiGeorge syndrome
(Figure 4B). However, these altered distribution profiles must
be interpreted in the context of age-matched healthy controls.
Therefore, correct interpretation relies on both patterns and
absolute numbers.
We integrated the data of the total cohort of genetically-
defined PID patients and the total set of healthy controls
to define which lymphocyte subsets were abnormal (i.e., the
absolute counts below the lower limit of normal, compared to
age-reference values) and calculated the percentage of patients
showing abnormal values (Table 2 and Supplementary Tables 2,
3). Per disease category the frequency of patients with defects
in any of the lymphoid subsets detected with the EuroFlow
PIDOT was determined. Naïve CD4, naïve CD8, and swiched
memory B-cells were the most frequently aberrant populations
(Figure S2). For example, in the category SCID all patients had
aberrancies in any of the T-cell subpopulations or in any of the B-
cell populations. More specifically, in all patients naïve T cells as
well as unswitched and switched memory B-cells were reduced.
Supplementary Tables 2, 3 give a further break down per T
and B-cell subset. In other PID categories similar characteristic
abnormalities were observed. For CID and PAD it was expected
that aberrancies in lymphoid subsets are expected, but this
dataset shows that also in patients with immune dysregulation
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FIGURE 3 | Flowcytometric analysis of B- and T-cell populations using the EuroFlow PID screening tube on controls and patients with SCID. From the top down, APS
plots of gated lymphocytes, B-cells, CD3+ T cells and TCRgd- T cells are shown. Lines depict a 2 standard deviation boundary of all controls combined. (A)
Multidimensional views of all lymphocyte subsets of a newborn, an infant, one Artemis-deficient and four RAG-deficient SCID patients. (B) Multidimensional views of
all lymphocyte subsets of a newborn, one IL7RA-deficient, three IL2RG-deficient and a ZAP70-deficient patient.
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FIGURE 4 | Multidimensional views of all lymphocyte subsets in healthy controls and PID patients. (A) Multidimensional views of all lymphocyte subsets of two
BTK-deficient patients, a CD40L deficiency, a patient with ALPS due to a mutation in FAS and healthy infants of 6 months and 3 years. (B) Multidimensional views of
all lymphocyte subsets of single examples of patients with Wiskott Aldrich syndrome (WASp), Ataxia Telangiectasia (ATM), DOCK8 deficiency and two patients with
DiGeorge syndrome.
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and defects in phagocyte and innate immunity aberrancies were
found with high frequencies. This illustrates that the PIDOT is
a powerful tool to detect aberrancies in a broad range of PID
with lymphocyte defects. As expected the PIDOT did not give
any abnormalities in complement deficiencies, since these PIDs
do not display any lymphocytes’ derangement.
Automated Analysis
The advantage of the large reference data set of normal samples
and well-annotated PID patient samples is that it can serve as
templates for prospective data analysis. In the Infinicyt software
program, an automatic analysis option has been included, which
can be applied on all samples provided that the samples were
processed, stained and measured according to the standardized
EuroFlow protocols. Also in case the lyophilized version of the
PIDOT is used, the data can be analyzed via this strategy (17).
This new feature provides per patient the multidimensional APS
plot, the absolute values of the lymphocyte subsets plotted in the
age-matched bar graph and the numerical table with values for
direct uploading in the electronic laboratory management and
patient systems. For a patient with APDS and GATA2 the output
is visualized in Figure 5. For the APDS patient this representation
clearly shows the combination of low level of B-cells–preGC and
especially (switched) memory B-cells, low naïve CD4 and CD8
cells and an expansion of the memory CD8 cell fractions, which
is characteristic for APDS (18). Also for the GATA2-deficient
patient displayed, the combined data show some characteristic
features: reduced B and NK cells in combination with numbers
of T-cell subsets which were below median but still within the
normal range. Table 2 and Supplementary Tables 2, 3 can be
consulted to verify how representative an immunophenotype
is for a given genetically defined PID. This new application of
EuroFlow software tools support diagnosis of PID.
DISCUSSION
In this study, we designed a single flow cytometry staining
tube, PIDOT, for analysis of defined B and T cell subsets and
validated its sensitivity performance on 250 healthy controls and
99 genetically-defined and IUIS-classified PID patients. This tube
is fully standardized with the aim to have fully comparable data
for international exchange of data and to support diagnosis of
PID. With the multicenter EuroFlow approach, the PIDOT was
designed over multiple rounds of design, testing in multiple
labs, evaluation, and redesign. In addition, an application of
new EuroFlow software tools with multidimensional pattern
recognition was designed with inclusion of maturation pathways
in multidimensional patterns (APS plots). Finally, we created
a reference data base for automated data analysis, which
can be implemented in diagnostic laboratories for routine
FIGURE 5 | Multidimensional views of all lymphocyte subsets in combination with the absolute values of all subpopulations plotted as red dots in the age-matched
reference bar graphs after automated analysis. (APDS) Patients with activated PI3K delta syndrome (APDS). (GATA2) Patient with GATA2 deficiency.
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diagnostics of patients suspected for PID. With this PIDOT, we
could analyze all major lymphocyte subsets and the important
lymphocyte subpopulations allowing the generation of data on
the absolute counts and frequency of the lymphocyte subsets and
a lymphocyte profile as APS view with a single tube. This tube can
readily be implemented in the diagnostics of PID.
The PIDOT serves as the central tube in the EuroFlow
algorithm for PID. Based on the results of the PIDOT other
tubes shall be used for more detailed analysis of B- and/or T-
cell subsets. For example, for patients with SCID the PIDOT
is a strong screening tool, that in combination with the
immunophenotyping of recent thymic emigrants in cases with
present yet abnormal T-cells can provide diagnostic information
with direct clinical consequences (Kalina et al. manuscript in
preparation, in this issue). In the PIDOT tube we choose CD27
and CD45RA as a marker for naïve T cells (CD27+CD45RA+),
while CD62L is used in the so called SCID-RTE tube together
with CD45RO and CD31 to confirm the absence of recent
thymic emigrants [Kalina et al. Manuscript in preparation, (19)].
Based on the flow cytometric results the treatment strategy
can be initiated even prior to the result of genetic testing.
The presence of T-cells in case of a clinical suspicion of SCID
should be interpreted with care. It is known that especially
RAG1 and RAG2 deficiencies can present with T-cells. The
presence of T-cells in a patient clinically presenting as SCID
can be due to hypomorphic mutation (with residual activity)
(20) Alternatively, T-cells can be of maternal origin (21). In
rare cases the presence of T-cells can be the result of reversion
mutations (22). In these cases, we recommend additional labeling
for SCID including CD31, CD62L, HLA-DR, and CD45RO for
further typing of T-cells (Kalina et al. manuscript in preparation).
For some PID disease categories, e.g., Common Variable
Immunodeficiency (CVID) it might be necessary to have a more
detailed phenotyping of the T- and B-cell subsets, e.g., with
respect to certain subsets expressing specific Ig subclasses (8, 23).
If the PIDOT is used as screening tube to test whether the
patient suffer from a PID, relative frequencies of naive CD4+
cells, as well as CD4 and CD8 effector memory cells were
most frequently aberrant. We propose that this approach is
used in any patient with a clinical suspicion of PID, because
multiple and clear abnormal values are indicative of severe
PID that requires adequate clinical management. In other,
less pronounced phenotypes, PID screening tube can direct
further evaluation including prioritization for NGS or gene
panel evaluation). In PIDs that do not affect the lymphoid
compartment (CGD, IRAK4 and complement deficiencies) no
aberrant populations were identified, indicating that this tube
is not useful for these categories. It will be of great value
to prospectively collect the data of PID analyzed with the
PIDOT to better define the characteristic pattern of aberrant
subsets in a large cohort of genetically defined PID. Moreover,
in combination with the clinical presentation and the exact
mutation, the spectrum of PID can be better defined.
Recently, a lyophilized version of the PID screening tube
has been developed and has proven to give the same results
as when antibodies are used the liquid form and are added
separately to the mixture. The advantage of using dried
tubes is that it is not only time-saving and less prone to
operational mistakes, but that it also significantly reduces the
time spent in antibody inventory management (ordering of
reagents and acceptance testing of antibodies (one single tube
vs. 12 individual antibodies), including all the corresponding
registrations (17), thus making the process suitable for any
clinical laboratory. The major advantage of the EuroFlow
approach using standardized protocols and flowcytometer
instruments setting is that the generated data can be fully
exchanged between laboratories and diagnostic centers, and will
allow the generation of databases of patient that are extremely
rare. Standardized EuroFlow multicolor flow cytometry is
relatively easy to adopt, as EuroFlow has created standard
operating protocols, published them on a eurofow.org website
and commented on their use in the literature. In order
to support the widespread adoption in reasonable quality
EuroFlow educational meetings are organized as well as Quality
Assessment (24).
Availability of the fully standardized PIDOT and accessibility
to EuroFlow reference data base allows any lab in the world
to perform standardized PID diagnostic, also in non-Western
countries, because all over the world 8-color flow cytometers are
now available, thanks to the HIV diagnostics and leukemia and
lymphoma diagnostics. In addition, the multidimensional data
analysis strategy and visualization will disclose new information,
which is otherwise lost if only frequencies and absolute numbers
of separate lymphocyte subsets are taken in consideration. With
these developments, a new dimension is added to flow cytometry
in the PID field in which the number of newly identified PIDs is
still increasing.
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